CN102307598A - TGF-β1抑制肽的药物制剂 - Google Patents

TGF-β1抑制肽的药物制剂 Download PDF

Info

Publication number
CN102307598A
CN102307598A CN2010800067872A CN201080006787A CN102307598A CN 102307598 A CN102307598 A CN 102307598A CN 2010800067872 A CN2010800067872 A CN 2010800067872A CN 201080006787 A CN201080006787 A CN 201080006787A CN 102307598 A CN102307598 A CN 102307598A
Authority
CN
China
Prior art keywords
tgf
peptide
cyclodextrin
emulsion
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800067872A
Other languages
English (en)
Chinese (zh)
Inventor
胡安·曼努埃尔·伊拉切·加雷塔
费尔南多·马丁内兹·加兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digna Biotech SL
Original Assignee
Digna Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech SL filed Critical Digna Biotech SL
Publication of CN102307598A publication Critical patent/CN102307598A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800067872A 2009-02-05 2010-02-04 TGF-β1抑制肽的药物制剂 Pending CN102307598A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900319 2009-02-05
ESP200900319 2009-02-05
PCT/ES2010/070062 WO2010089443A2 (es) 2009-02-05 2010-02-04 FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1

Publications (1)

Publication Number Publication Date
CN102307598A true CN102307598A (zh) 2012-01-04

Family

ID=42320987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800067872A Pending CN102307598A (zh) 2009-02-05 2010-02-04 TGF-β1抑制肽的药物制剂

Country Status (10)

Country Link
US (1) US20110294734A1 (cg-RX-API-DMAC7.html)
EP (1) EP2394666A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012516879A (cg-RX-API-DMAC7.html)
CN (1) CN102307598A (cg-RX-API-DMAC7.html)
AU (1) AU2010210033A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1008815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2750559A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011008261A (cg-RX-API-DMAC7.html)
RU (1) RU2011136694A (cg-RX-API-DMAC7.html)
WO (1) WO2010089443A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154567A2 (en) * 2011-05-06 2012-11-15 Albert Einstein College Of Medicine Of Yeshiva University Human invasion signature for prognosis of metastatic risk
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
BR112015027569A2 (pt) * 2013-05-10 2017-09-19 Southern Res Inst compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CN107533040B (zh) 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
KR101841748B1 (ko) 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
KR102779666B1 (ko) * 2020-12-23 2025-03-12 한국과학기술연구원 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CN1839149A (zh) * 2003-08-22 2006-09-27 西玛生物医学信息公司 能够结合转化生长因子β1(TGF－β1)的肽
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008003685A1 (de) * 2006-07-06 2008-01-10 Henkel Ag & Co. Kgaa O/w-emulsion
WO2008013928A2 (en) * 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215520A (en) * 1991-09-17 1993-06-01 Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for delivering an active substance topically or percutaneously
US6132739A (en) * 1998-09-01 2000-10-17 Amway Corporation Makeup compositions and methods of making same
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
ES2371026T3 (es) * 2001-10-19 2011-12-26 Atritech, Inc. Dispositivo de oclusión ajustable en la orejuela auricular izquierda.
WO2003048323A2 (en) 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7279503B1 (en) * 2004-11-02 2007-10-09 Siltech Llc Water in oil emulsions
SG179457A1 (en) * 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CN1839149A (zh) * 2003-08-22 2006-09-27 西玛生物医学信息公司 能够结合转化生长因子β1(TGF－β1)的肽
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008003685A1 (de) * 2006-07-06 2008-01-10 Henkel Ag & Co. Kgaa O/w-emulsion
WO2008013928A2 (en) * 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
WO2021037290A3 (zh) * 2019-08-27 2021-04-15 南京安吉生物科技有限公司 一种融合多肽及其应用
GB2600594A (en) * 2019-08-27 2022-05-04 Nanjing Anji Biological Tech Co Ltd Fused polypeptide and use thereof

Also Published As

Publication number Publication date
MX2011008261A (es) 2011-09-01
CA2750559A1 (en) 2010-08-12
BRPI1008815A2 (pt) 2018-02-14
AU2010210033A1 (en) 2011-08-04
RU2011136694A (ru) 2013-03-10
US20110294734A1 (en) 2011-12-01
WO2010089443A3 (es) 2010-10-21
WO2010089443A2 (es) 2010-08-12
JP2012516879A (ja) 2012-07-26
EP2394666A2 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
CN102307598A (zh) TGF-β1抑制肽的药物制剂
Deshayes et al. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes
CN102026667B (zh) 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
Liu et al. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis
JP6689378B2 (ja) 巨大分子の経口送達のための細胞浸透性ペプチド及びテトラエーテル脂質を含むリポソーム
Wang et al. Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human retinal pigment epithelial cells
CN109789188A (zh) 具有低峰-谷比的pth化合物
JP2000505788A (ja) 巨大分子送達用の親油性ペプチド
JP7442595B2 (ja) ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤
Diedrichsen et al. Revealing the importance of carrier-cargo association in delivery of insulin and lipidated insulin
Tavornvipas et al. Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor
JP2022535555A (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
CN103827187A (zh) 用β片层多肽嵌段共聚物功能化的生物活性碳纳米管复合材料及其制备方法
EP4049653B1 (en) Injectable intraocular microgel as drug delivery system, and hydrogel comprising same
Kulkarni et al. Esterase-mediated sustained release of peptide-based therapeutics from a self-assembled injectable hydrogel
US20220040109A1 (en) Kidney-targeting drug delivery carrier
Rodríguez-Cabello et al. Elastin-like proteins: molecular design for self-assembling
Hao et al. Self-assembled doxorubicin prodrug riding on the albumin express train enable tumor targeting and bio-activation
CN116997337A (zh) 半乳糖缺陷型免疫球蛋白的双官能降解剂
JP5769420B2 (ja) Ｎｃａｍ由来の新規ペプチド（ｆｇｌｓ）
Mok et al. Dissolution of biomacromolecules in organic solvents by nano-complexing with poly (ethylene glycol)
Sampathi et al. Modified Cyclodextrin‐Based Thermosensitive In Situ Gel for Voriconazole Ocular Delivery Against Fungal Keratitis
Suthar et al. Investigation on potential of chitosan nanoparticles for oral bioavailability enhancement of risedronate sodium
JP2022507477A (ja) チオアミド含有構成物
ITMI20111866A1 (it) Polietilenglicoli modificati e loro complessi supramolecolari con macromolecole biologicamente attive

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120104

C20 Patent right or utility model deemed to be abandoned or is abandoned